These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

169 related articles for article (PubMed ID: 26682038)

  • 1. Protocol for a randomised, double-blind, placebo-controlled study of grass allergen immunotherapy tablet for seasonal allergic rhinitis: time course of nasal, cutaneous and immunological outcomes.
    Steveling EH; Lao-Araya M; Koulias C; Scadding G; Eifan A; James LK; Dumitru A; Penagos M; Calderón M; Andersen PS; Shamji M; Durham SR
    Clin Transl Allergy; 2015; 5():43. PubMed ID: 26682038
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effect of 2 Years of Treatment With Sublingual Grass Pollen Immunotherapy on Nasal Response to Allergen Challenge at 3 Years Among Patients With Moderate to Severe Seasonal Allergic Rhinitis: The GRASS Randomized Clinical Trial.
    Scadding GW; Calderon MA; Shamji MH; Eifan AO; Penagos M; Dumitru F; Sever ML; Bahnson HT; Lawson K; Harris KM; Plough AG; Panza JL; Qin T; Lim N; Tchao NK; Togias A; Durham SR;
    JAMA; 2017 Feb; 317(6):615-625. PubMed ID: 28196255
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Sublingual immunotherapy with once-daily grass allergen tablets: a randomized controlled trial in seasonal allergic rhinoconjunctivitis.
    Durham SR; Yang WH; Pedersen MR; Johansen N; Rak S
    J Allergy Clin Immunol; 2006 Apr; 117(4):802-9. PubMed ID: 16630937
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Grass allergen tablet immunotherapy relieves individual seasonal eye and nasal symptoms, including nasal blockage.
    Durham SR; Riis B
    Allergy; 2007 Aug; 62(8):954-7. PubMed ID: 17620075
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Protocol for a double-blind randomised controlled trial of low dose intradermal grass pollen immunotherapy versus a histamine control on symptoms and medication use in adults with seasonal allergic rhinitis (PollenLITE).
    Slovick A; Douiri A; Kelly J; Guerra A; Muir R; Tsioulos K; Murphy C; Shamji MH; Ying S; Durham SR; Till SJ
    Clin Transl Allergy; 2013 Aug; 3(1):27. PubMed ID: 23965180
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Allergy immunotherapy tablet: Grazax® for the treatment of grass pollen allergy.
    Senna GE; Calderon M; Milani M
    Expert Rev Clin Immunol; 2011 Jan; 7(1):21-7. PubMed ID: 21162646
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Safety and tolerability of an SQ-standardized GRAss ALlergy immunotherapy tablet (GRAZAX®) in a real-life setting for three consecutive seasons - the GRAAL trial.
    Wessel F; Chartier A; Meunier JP; Magnan A
    Clin Drug Investig; 2012 Jul; 32(7):451-63. PubMed ID: 22594491
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Lack of effect of Timothy grass pollen sublingual immunotherapy tablet on birch pollen-induced allergic rhinoconjunctivitis in an environmental exposure unit.
    Ellis AK; Tenn MW; Steacy LM; Adams DE; Day AG; Walker TJ; Nolte H
    Ann Allergy Asthma Immunol; 2018 May; 120(5):495-503.e2. PubMed ID: 29432967
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Immunologic effects and tolerability profile of in-season initiation of a standardized-quality grass allergy immunotherapy tablet: a phase III, multicenter, randomized, double-blind, placebo-controlled trial in adults with grass pollen-induced rhinoconjunctivitis.
    Reich K; Gessner C; Kroker A; Schwab JA; Pohl W; Villesen H; Wüstenberg E; Emminger W
    Clin Ther; 2011 Jul; 33(7):828-40. PubMed ID: 21741092
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Long-term clinical efficacy in grass pollen-induced rhinoconjunctivitis after treatment with SQ-standardized grass allergy immunotherapy tablet.
    Durham SR; Emminger W; Kapp A; Colombo G; de Monchy JG; Rak S; Scadding GK; Andersen JS; Riis B; Dahl R
    J Allergy Clin Immunol; 2010 Jan; 125(1):131-8.e1-7. PubMed ID: 20109743
    [TBL] [Abstract][Full Text] [Related]  

  • 11. An extract of Timothy-grass pollen used as sublingual immunotherapy for summer hay fever.
    Kay AB
    Drugs Today (Barc); 2007 Dec; 43(12):841-8. PubMed ID: 18174969
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Specific immunotherapy in local allergic rhinitis: A randomized, double-blind placebo-controlled trial with Phleum pratense subcutaneous allergen immunotherapy.
    Rondón C; Blanca-López N; Campo P; Mayorga C; Jurado-Escobar R; Torres MJ; Canto G; Blanca M
    Allergy; 2018 Apr; 73(4):905-915. PubMed ID: 29168570
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Specific immunotherapy with SQ standardized grass allergen tablets in asthmatics with rhinoconjunctivitis.
    Dahl R; Stender A; Rak S
    Allergy; 2006 Feb; 61(2):185-90. PubMed ID: 16409194
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Sublingual immunotherapy for allergic rhinitis.
    Wilson DR; Torres LI; Durham SR
    Cochrane Database Syst Rev; 2003; (2):CD002893. PubMed ID: 12804442
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Sublingual or subcutaneous immunotherapy for seasonal allergic rhinitis: an indirect analysis of efficacy, safety and cost.
    Dranitsaris G; Ellis AK
    J Eval Clin Pract; 2014 Jun; 20(3):225-38. PubMed ID: 24444390
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Intradermal grass pollen immunotherapy increases T
    Slovick A; Douiri A; Muir R; Guerra A; Tsioulos K; Hay E; Lam EPS; Kelly J; Peacock JL; Ying S; Shamji MH; Cousins DJ; Durham SR; Till SJ
    J Allergy Clin Immunol; 2017 Jun; 139(6):1830-1839.e13. PubMed ID: 27773851
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Polyvalent Mechanical Bacterial Lysate Administration Improves the Clinical Course of Grass Pollen-Induced Allergic Rhinitis in Children: A Randomized Controlled Trial.
    Janeczek K; Emeryk A; Rachel M; Duma D; Zimmer Ł; Poleszak E
    J Allergy Clin Immunol Pract; 2021 Jan; 9(1):453-462. PubMed ID: 32858239
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Sublingual grass allergen tablet immunotherapy provides sustained clinical benefit with progressive immunologic changes over 2 years.
    Dahl R; Kapp A; Colombo G; de Monchy JG; Rak S; Emminger W; Riis B; Grønager PM; Durham SR
    J Allergy Clin Immunol; 2008 Feb; 121(2):512-518.e2. PubMed ID: 18155284
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficacy of house dust mite sublingual immunotherapy tablet in North American adolescents and adults in a randomized, placebo-controlled trial.
    Nolte H; Bernstein DI; Nelson HS; Kleine-Tebbe J; Sussman GL; Seitzberg D; Rehm D; Kaur A; Li Z; Lu S
    J Allergy Clin Immunol; 2016 Dec; 138(6):1631-1638. PubMed ID: 27521719
    [TBL] [Abstract][Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 9.